AtriCure Dividend

Dividend criteria checks 0/6

AtriCure does not have a record of paying a dividend.

Key information

n/a

Dividend yield

n/a

Payout ratio

Industry average yield	1.8%
Next dividend pay date	n/a
Ex dividend date	n/a
Dividend per share	n/a
Earnings per share	-US$0.52
Dividend yield forecast in 3Y	0%

Recent dividend updates

No updates

Recent updates

Is AtriCure (NASDAQ:ATRC) Using Debt In A Risky Way?

Nov 29

AtriCure, Inc.'s (NASDAQ:ATRC) Intrinsic Value Is Potentially 99% Above Its Share Price

Sep 27

An Intrinsic Calculation For AtriCure, Inc. (NASDAQ:ATRC) Suggests It's 29% Undervalued

Aug 02

AtriCure: 5x Sales For A Series Of Impeding Losses? No Thanks

Jun 13

Is AtriCure (NASDAQ:ATRC) Weighed On By Its Debt Load?

Jun 08

Is It Time To Consider Buying AtriCure, Inc. (NASDAQ:ATRC)?

May 08

Is AtriCure, Inc. (NASDAQ:ATRC) Expensive For A Reason? A Look At Its Intrinsic Value

Apr 11

Is AtriCure (NASDAQ:ATRC) A Risky Investment?

Feb 18

Why AtriCure, Inc. (NASDAQ:ATRC) Could Be Worth Watching

Jan 20

Robust Earnings May Not Tell The Whole Story For AtriCure (NASDAQ:ATRC)

Nov 11

Does AtriCure (NASDAQ:ATRC) Have A Healthy Balance Sheet?

Oct 21

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if ATRC's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ATRC's dividend payments have been increasing.

Dividend Yield vs Market

AtriCure Dividend Yield vs Market

How does ATRC dividend yield compare to the market?
Segment	Dividend Yield
Company (ATRC)	n/a
Market Bottom 25% (US)	1.6%
Market Top 25% (US)	4.8%
Industry Average (Medical Equipment)	1.8%
Analyst forecast in 3 Years (ATRC)	0%

Notable Dividend: Unable to evaluate ATRC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ATRC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate ATRC's payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as ATRC has not reported any payouts.

Discover strong dividend paying companies


Price	7D	1Y
Mkt Cap	P/E	Growth


Price	7D	1Y
Mkt Cap	P/E	Growth


Price	7D	1Y
Mkt Cap	P/E	Growth


Price	7D	1Y
Mkt Cap	P/E	Growth

AtriCure Dividend

Dividend criteria checks 0/6

Key information

Recent dividend updates

Recent updates

Is AtriCure (NASDAQ:ATRC) Using Debt In A Risky Way?

Consensus EPS estimates upgraded to US$0.70 loss

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

AtriCure, Inc. Provides Revenue Guidance for the 2023

AtriCure, Inc. to Report Q3, 2023 Results on Nov 01, 2023

AtriCure, Inc.'s (NASDAQ:ATRC) Intrinsic Value Is Potentially 99% Above Its Share Price

Now 24% undervalued

Health Check: How Prudently Does AtriCure (NASDAQ:ATRC) Use Debt?

Consensus estimates of losses per share improve by 15%

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Atricure, Inc. Provides Revenue Guidance for the Year 2023

AtriCure, Inc. to Report Q2, 2023 Results on Jul 25, 2023

AtriCure, Inc.'s (NASDAQ:ATRC) Share Price Matching Investor Opinion

Independent Director recently sold US$203k worth of stock

Independent Director notifies of intention to sell stock

Chief Legal Officer notifies of intention to sell stock

Atricure, Inc. Provides Revenue Guidance for Full Year 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Is AtriCure (NASDAQ:ATRC) Weighed On By Its Debt Load?

Independent Director exercised options to buy US$393k worth of stock.

Now 21% undervalued after recent price drop

Independent Director exercised options to buy US$799k worth of stock.

Calculating The Intrinsic Value Of AtriCure, Inc. (NASDAQ:ATRC)

Consensus EPS estimates fall by 31%

Price target decreased by 7.7% to US$56.33

Full year 2022 earnings: EPS exceeds analyst expectations

What Does AtriCure, Inc.'s (NASDAQ:ATRC) Share Price Indicate?

AtriCure, Inc. Announces the First Patient Treated in the LeAAPS™ Clinical Trial

AtriCure, Inc. to Report Q4, 2022 Results on Feb 21, 2023

AtriCure, Inc. Provides Earnings Guidance for 2023

Is AtriCure (NASDAQ:ATRC) Using Debt In A Risky Way?

Now 21% undervalued

Price target decreased to US$57.83

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

AtriCure, Inc. Provides Earnings Guidance for the Full Year of 2022

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

AtriCure, Inc. to Report Q3, 2022 Results on Nov 01, 2022

Chief Scientific Officer recently sold US$229k worth of stock

Chief Scientific Officer notifies of intention to sell stock

Insider notifies of intention to sell stock

Is Now An Opportune Moment To Examine AtriCure, Inc. (NASDAQ:ATRC)?

Independent Director exercised options to buy US$642k worth of stock.

Insider notifies of intention to sell stock

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

AtriCure, Inc. Provides Earnings Guidance for the Full Year of 2022

An Intrinsic Calculation For AtriCure, Inc. (NASDAQ:ATRC) Suggests It's 29% Undervalued

Insider notifies of intention to sell stock

Price target decreased to US$69.50

AtriCure, Inc. to Report Q2, 2022 Results on Aug 02, 2022

Price target decreased to US$74.83

Insider notifies of intention to sell stock

Investor sentiment deteriorated over the past week

AtriCure: 5x Sales For A Series Of Impeding Losses? No Thanks

Is AtriCure (NASDAQ:ATRC) Weighed On By Its Debt Load?

AtriCure, Inc. Announces the First Patient Treated in the HEAL-IST Clinical Trial

AtriCure, Inc. Announces the Appointment of Deborah Yount as Chief Human Resources Officer

Chief Human Resources Officer notifies of intention to sell stock

Investor sentiment deteriorated over the past week

Is It Time To Consider Buying AtriCure, Inc. (NASDAQ:ATRC)?

Price target decreased to US$79.86

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

AtriCure, Inc. Provides Financial Guidance for the Full Year 2022

Price target decreased to US$87.29

AtriCure, Inc. Launches Encompass® Clamp, A Part of Isolator Synergy™ Ablation System

AtriCure, Inc., Annual General Meeting, May 25, 2022

Is AtriCure, Inc. (NASDAQ:ATRC) Expensive For A Reason? A Look At Its Intrinsic Value

Chief Human Resources Officer notifies of intention to sell stock

Consensus forecasts updated

Now 22% undervalued after recent price drop

Is AtriCure (NASDAQ:ATRC) A Risky Investment?

Chief Human Resources Officer notifies of intention to sell stock

Price target decreased to US$87.29

Full year 2021 earnings: EPS misses analyst expectations